Innoviva, Inc. Common Stock (INVA) — Analysis Summary
Innoviva, Inc. Common Stock (INVA) has a market cap of $1.53B with year-over-year revenue growth of +14.7%. Net margin stands at 65.9%. The stock trades at a P/E ratio of 4.3.
Key Takeaways
- Revenue changed +14.7% year-over-year
- Net margin of 65.9%
- P/E ratio of 4.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, INVA posted revenue growth of +14.7% and trades at a P/E of 4.3.
Innoviva, Inc. Common Stock (INVA)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
159
Headquarters
BURLINGAME, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.00
Dividend Yield
4.66%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.